Pain drug developer Adynxx enrolls first trial

Adynxx founder Julien Mamet.

Adynxx Inc., led by a team that has built and sold three other Bay Area drug developers over the past decade, said Tuesday that it has completed enrollment in an early-stage drug trial that could take the pain out of surgery. The 30-person, Phase I study is the first in-human test of AYX-1, the San Francisco company’s experimental preventative treatment for post-surgical pain. The study of healthy volunteers is designed to test the drug’s safety. Adynxx leaders expect to move the drug into a 90- to 100-patient Phase II efficacy trial in the fourth quarter.